SCHEMBL3301539

SCHEMBL3301539

Cc1cc(Nc2ccnc(Nc3ccc(S(=O)(=O)N4CCC(O)(CN5CC=CC5)CC4)cc3)n2)ccc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 11/20 0.44
CHUK O15111 10/20 0.44
CDK2 P24941 3/20 0.43
CCNE1 P24864 2/20 0.43
CDK4 P11802 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.41
JAK2 O60674 2/20 0.40
JAK3 P52333 2/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
HTR2A P28223 1/20 0.38
AURKA O14965 1/20 0.37
MAP4K4 O95819 1/20 0.37
PIM1 P11309 1/20 0.37
MAPK8 P45983 1/20 0.37
GSK3B P49841 1/20 0.37
AURKB Q96GD4 1/20 0.37
HIPK2 Q9H2X6 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3298024 0.93 IKBKB (0.44) IKBKBCHUKCDK2CCNE1CDK4
SCHEMBL3295573 0.93 IKBKB (0.44) IKBKBCHUKCDK2CCNE1CDK4
SCHEMBL3299415 0.92 MAPT (0.45) IKBKBCHUKCDK2CCNE1CDK4
SCHEMBL3306739 0.92 IKBKB (0.43) IKBKBCHUKCDK2CCNE1CDK4
SCHEMBL3306581 0.91 CDK2 (0.45) IKBKBCHUKCDK2CCNE1CDK4
SCHEMBL3301214 0.90 IKBKB (0.42) IKBKBCHUKCDK2CCNE1CDK4
SCHEMBL3299865 0.90 CDK4 (0.48) IKBKBCHUKCDK2CCNE1CDK4
SCHEMBL3302590 0.89 IKBKB (0.42) IKBKBCHUKCDK2CCNE1CDK4
SCHEMBL13392719 0.89 IKBKB (0.43) IKBKBCHUKCDK2CCNE1CDK4
SCHEMBL3300040 0.89 IKBKB (0.41) IKBKBCHUKCDK2CCNE1CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-04-15 US disclosed
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-04-15 US disclosed
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS CHUK, IKBKB, IKBKE IKBKB 2/4885CHUK 1/4885CDK2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.